key: cord-1004404-0plp1fsc
authors: Ader, Florence
title: An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19 – Final results
date: 2022-05-07
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2022.04.016
sha: 2b33ffc203cae58bb9172c4b5324bf229164cb7f
doc_id: 1004404
cord_uid: 0plp1fsc

nan

We published in the December 2021 issue of Clinical Microbiology and Infection the 21 preliminary results of the DisCoVeRy trial regarding the efficacy of lopinavir/ritonavir, 22 lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with 23 COVID-19 [1] . These three experimental repurposed treatments did not show clinical or 24 virological benefit in the studied population. Of note, the number of patients included was low 25 as inclusion in those arms of the trial was prematurely stopped by the DSMB. Here, after 26 completion of data monitoring, we report the final analysis, including two secondary endpoints 27 which were not previously reported. 28

Briefly, the DisCoVeRy trial is a phase 3 open-label randomized, controlled trial evaluating the 29 efficacy and safety of repurposed drugs in adults hospitalized for COVID-19, sponsored by 30 (Table) . 48 Some modifications were observed regarding the secondary outcomes; full results are available 49 elsewhere [2]. In-hospital mortality was not affected by any treatment arm (Table) . Three-50 month mortality was significantly higher for participants assigned to the lopinavir/ritonavir plus 51 IFN-ß-1a arm than participants assigned to the control arm, while no difference was observed 52 for the lopinavir/ritonavir and the hydroxychloroquine arms (Table) . In addition, participants 53 assigned to the lopinavir/ritonavir plus IFN-ß-1a had a significantly longer time to hospital 54 discharge, either when considered as a single endpoint or as composite endpoints (Table) . 55

The previously reported higher rate of participants experiencing any adverse event in the 56 lopinavir/ritonavir plus IFN-ß-1a arm was no longer significant in the final dataset: control arm, 57 n=113/149 (75.8%); lopinavir/ritonavir plus IFN-ß-1a arm, n=122/145 (84.1%, P=0.08 vs. 58 control); it remained significantly higher in the lopinavir/ritonavir arm (n=125/147, 85.0%, 59 P=0.05 vs. control). Regarding the reporting of any serious adverse event, the proportion 60 remained significantly higher in both lopinavir/ritonavir-containing arms than in the control 61 arm: control arm, n=58/149 (38.9%); lopinavir/ritonavir arm, n=76/147 (51.7%, P=0.02 vs. 62 results of the lopinavir/ritonavir plus IFN-ß-1a arm raise interesting questions. Indeed, because 69 defects in IFN signalling pathways have been shown to be associated with severe COVID-19 70 [3] , one could assume that IFN treatment might improve COVID-19 clinical outcome. Here, 71 results suggest a detrimental effect of IFN-ß-1a treatment: participants assigned to the 72 lopinavir/ritonavir plus IFN-β-1a arm had significantly longer time to hospital discharge (alone 73 or combined in composite endpoints) and higher 90-day mortality than untreated controls, 74 whereas these outcomes were not significantly different between participants assigned to 75 lopinavir/ritonavir alone or to the control arm. Overall, this suggests that IFN-ß-1a 76 administration is not always appropriate, and that screening of IFN signalling pathways may be 77 required to identify patients who would most benefit from IFN treatment [4] . 

Impaired type I 131 interferon activity and inflammatory responses in severe COVID-19 patients

Specialized interferon action in COVID-19